These findings uncover previously uncharacterized hypoxic reprogramming during vascular remodeling, and suggest that blocking of CD146-HIF-1α cross-regulation represents a suitable avenue for developing effective therapies against PAH. The gene discussed is MCAM; the disease is pulmonary arterial hypertension.